Such observation was mechanistically corroborated by evidence that pharmacological interactions between BRAF and MEK inhibitors were not substantially modified in isogenic cellular models of lung and colorectal cancer differing for KRAS status. The gene discussed is BRAF; the disease is colorectal cancer.